Allstate Corp Increases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Allstate Corp increased its shareholding in Thermo Fisher Scientific Inc. by 22.3% during the first quarter, holding 13,911 shares valued at approximately $6.92 million.
• The CEO, Marc N. Casper, sold 295 shares at about $500.04 per share, while insiders collectively sold 18,896 shares valued at around $8.59 million in the last quarter.
• Thermo Fisher Scientific reported $5.36 earnings per share for the last quarter, surpassing analysts' expectations, and set Q3 2025 guidance at $5.460-$5.510 EPS.

Allstate Corp raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 22.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,911 shares of the medical research company's stock after acquiring an additional 2,540 shares during the quarter. Allstate Corp's holdings in Thermo Fisher Scientific were worth $6,922,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. D.B. Root & Company LLC raised its holdings in shares of Thermo Fisher Scientific by 21.7% during the first quarter. D.B. Root & Company LLC now owns 1,120 shares of the medical research company's stock worth $557,000 after acquiring an additional 200 shares during the period. 1832 Asset Management L.P. grew its stake in shares of Thermo Fisher Scientific by 45.1% in the first quarter. 1832 Asset Management L.P. now owns 788,775 shares of the medical research company's stock valued at $392,494,000 after acquiring an additional 245,212 shares in the last quarter. Compound Planning Inc. boosted its holdings in Thermo Fisher Scientific by 52.4% in the 1st quarter. Compound Planning Inc. now owns 3,992 shares of the medical research company's stock valued at $1,987,000 after purchasing an additional 1,373 shares during the period. Bragg Financial Advisors Inc raised its position in shares of Thermo Fisher Scientific by 4.2% in the 1st quarter. Bragg Financial Advisors Inc now owns 13,498 shares of the medical research company's stock valued at $6,717,000 after buying an additional 538 shares in the last quarter. Finally, Norinchukin Bank The raised its position in shares of Thermo Fisher Scientific by 15.0% in the 1st quarter. Norinchukin Bank The now owns 19,430 shares of the medical research company's stock valued at $9,668,000 after buying an additional 2,531 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $9.2570 on Monday, hitting $490.7330. 1,044,331 shares of the company traded hands, compared to its average volume of 2,475,416. The stock has a market capitalization of $185.31 billion, a P/E ratio of 28.38, a price-to-earnings-growth ratio of 2.67 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The business has a 50-day simple moving average of $443.02 and a 200 day simple moving average of $455.80.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Analysts Set New Price Targets

Several brokerages have issued reports on TMO. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Barclays raised their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a report on Thursday, July 24th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. UBS Group lifted their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Finally, William Blair started coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They set an "outperform" rating for the company. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 295 shares of the company's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $500.04, for a total value of $147,511.80. Following the completion of the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $57,591,606.96. The trade was a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,896 shares of company stock worth $8,593,838. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.